CB2 Receptors in Skin Cells Suppressed Chemo-Induced Nerve Pain in Mice
CB2 cannabinoid receptors expressed in previously unrecognized skin cell populations suppressed chemotherapy-induced nerve pain in mice, pointing to a peripheral mechanism that avoids brain-related side effects.
Quick Facts
What This Study Found
CB2 agonists (AM1710 and LY2828360) suppressed paclitaxel-induced mechanical and cold allodynia in mice. The antiallodynic effect was blocked by a peripherally restricted CB2 antagonist, and local injection into the paw was effective, indicating a peripheral mechanism. CB2 was found in skin keratinocytes, Langerhans cells, dendritic cells, and Merkel cells.
Key Numbers
CB2 found in keratinocytes, Langerhans cells, dendritic cells, and Merkel cells; paclitaxel treatment dynamically increased Langerhans cells in the epidermis; local paw injection was effective
How They Did This
Used transgenic CB2-EGFP reporter mice to visualize CB2-expressing cell types. Tested structurally distinct CB2 agonists in a paclitaxel-induced neuropathy model. Combined behavioral testing with immunohistochemistry and mass cytometry.
Why This Research Matters
Chemotherapy-induced peripheral neuropathy affects many cancer patients and has few effective treatments. A peripheral CB2 mechanism that avoids the psychoactive effects of CB1 activation could lead to targeted pain therapies.
The Bigger Picture
CB2 receptors have been a "holy grail" target for pain relief without intoxication. This study identifies specific skin cells as the site of action, potentially simplifying drug development toward topical or locally acting treatments.
What This Study Doesn't Tell Us
Animal study in transgenic mice. CB2 expression patterns may differ in humans. The reporter gene approach may not capture all CB2-expressing cell types.
Questions This Raises
- ?Would topical CB2 agonists be effective for chemotherapy neuropathy in humans?
- ?Do the Langerhans cell changes represent a therapeutic target or a side effect of treatment?
Trust & Context
- Key Stat:
- CB2 found in 4 previously unrecognized skin cell types
- Evidence Grade:
- Well-designed animal study with transgenic reporter mice and multiple verification methods, but human translation is unconfirmed.
- Study Age:
- Published in 2022
- Original Title:
- A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.
- Published In:
- Pain, 163(5), 834-851 (2022)
- Authors:
- Lin, Xiaoyan(3), Xu, Zhili(2), Carey, Lawrence, Romero, Julian, Makriyannis, Alexandros, Hillard, Cecilia J, Ruggiero, Elizabeth, Dockum, Marilyn, Houk, George, Mackie, Ken, Albrecht, Phillip J, Rice, Frank L, Hohmann, Andrea G
- Database ID:
- RTHC-04011
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could this lead to a pain cream for chemo patients?
The study showed that activating CB2 receptors locally in the paw suppressed nerve pain in mice, and these receptors are expressed in skin cells. This supports the concept of topical CB2-targeted treatments, though human trials are needed.
What is the advantage of targeting CB2 instead of CB1?
CB1 receptors are concentrated in the brain and cause the "high" from cannabis. CB2 receptors are found peripherally (including in skin cells) and can reduce pain without psychoactive effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04011APA
Lin, Xiaoyan; Xu, Zhili; Carey, Lawrence; Romero, Julian; Makriyannis, Alexandros; Hillard, Cecilia J; Ruggiero, Elizabeth; Dockum, Marilyn; Houk, George; Mackie, Ken; Albrecht, Phillip J; Rice, Frank L; Hohmann, Andrea G. (2022). A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.. Pain, 163(5), 834-851. https://doi.org/10.1097/j.pain.0000000000002502
MLA
Lin, Xiaoyan, et al. "A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.." Pain, 2022. https://doi.org/10.1097/j.pain.0000000000002502
RethinkTHC
RethinkTHC Research Database. "A peripheral CB2 cannabinoid receptor mechanism suppresses c..." RTHC-04011. Retrieved from https://rethinkthc.com/research/lin-2022-a-peripheral-cb2-cannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.